• Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

    Read more
  • Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

    Read more
  • Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

    Read more
  • Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120

    Read more
  • Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)

    Read more
  • Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Read more
  • Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Read more
  • Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

    Read more
  • Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine

    Read more
  • Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology

    Read more
  • Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy

    Read more
  • Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology

    Read more
  • Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

    Read more
  • Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

    Read more
  • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

    Read more
  • Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

    Read more
  • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics Named the Stock Exchange Company of the Year

    Read more
  • Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

    Read more
  • Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million

    Read more
  • Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics initiates public offering of shares

    Read more
  • BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

    Read more
  • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

    Read more
  • Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

    Read more
  • Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

    Read more
  • EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

    Read more
  • Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

    Read more
  • Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

    Read more
  • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

    Read more
  • Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

    Read more
  • Ryvu Therapeutics to Participate in Upcoming Investor Conferences

    Read more
  • Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

    Read more
  • Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    Read more
  • Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

    Read more
  • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

    Read more
  • Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

    Read more
  • Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

    Read more
  • Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

    Read more
  • Ryvu announces option to license inflammation program exercised by Galapagos NV

    Read more
  • Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

    Read more
  • Ryvu Therapeutics Reports Q3 2021 Financial Results

    Read more
  • Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    Read more
  • Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

    Read more
  • Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

    Read more
  • Ryvu Therapeutics Reports 2021 Half-Year Financial Results

    Read more
  • Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

    Read more
  • Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

    Read more
  • Ryvu Therapeutics to participate in upcoming global investor conferences

    Read more
  • FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Read more
  • Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

    Read more
  • Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

    Read more
  • Ryvu Therapeutics among the founding members of 30% Club Poland

    Read more
  • Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

    Read more
  • Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

    Read more
  • SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

    Read more
  • Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

    Read more
  • Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

    Read more
  • Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

    Read more
  • Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

    Read more
  • Ryvu Therapeutics Reports First Quarter 2021 Financial Results

    Read more
  • Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

    Read more
  • Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Read more
  • Ryvu Therapeutics at BIO-Europe Spring

    Read more
  • Ryvu Therapeutics reports financial results for 2020

    Read more
  • Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

    Read more
  • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

    Read more
  • Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

    Read more
  • Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

    Read more
  • Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

    Read more
  • "Dream with Ryvu" - a corporate movie by Ryvu Therapeutics

    Read more
  • Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

    Read more
  • Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

    Read more
  • Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

    Read more
  • Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

    Read more
  • Ryvu Therapeutics Reports Q3 2020 Financial Results

    Read more
  • Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

    Read more
  • Ryvu Therapeutics at BIO-Europe 2020

    Read more
  • Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

    Read more
  • First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

    Read more
  • Ryvu Therapeutics Reports 2020 Half-Year Financial Results

    Read more
  • Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

    Read more
  • Ryvu Therapeutics raised over USD 36 million from its share issue

    Read more
  • The share issue price in Ryvu Therapeutics public offering set at PLN 60

    Read more
  • Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

    Read more
  • Ryvu Therapeutics Reports First Quarter 2020 Financial Results

    Read more
  • Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

    Read more
  • NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

    Read more
  • Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

    Read more
  • Ryvu Therapeutics at BIO Digital 2020

    Read more
  • Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

    Read more
  • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

    Read more
  • Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

    Read more
  • Galapagos and Ryvu announce research collaboration

    Read more
  • Ryvu Therapeutics Reports Annual 2019 Financial Results

    Read more
  • Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

    Read more
  • Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia

    Read more
  • Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

    Read more
  • Ryvu Therapeutics at BIO-Europe Spring 2020

    Read more
  • Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference

    Read more
  • Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept

    Read more
  • Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors

    Read more
  • Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules

    Read more
  • Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

    Read more
  • Ryvu Therapeutics to Present at BIO-Europe 2019

    Read more
  • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

    Read more
  • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    Read more
  • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

    Read more
  • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

    Read more
  • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    Read more
  • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

    Read more
  • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

    Read more
  • Selvita to Present at Upcoming Conferences in September

    Read more
  • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

    Read more
  • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

    Read more
  • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

    Read more
  • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

    Read more
  • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

    Read more
  • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Read more
  • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

    Read more
  • Selvita to Present at Biotech Showcase 2019 in San Francisco

    Read more
  • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

    Read more
  • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

    Read more
  • Selvita to present new data from its oncology programs at the upcoming SITC 2018

    Read more
  • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

    Read more
  • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

    Read more
  • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

    Read more
  • Selvita publishes research results on SEL24 in Oncotarget

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

    Read more
  • Selvita Announces Successful Completion of $41 M Book Building

    Read more
  • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

    Read more
  • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

    Read more
  • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita and Menarini present together at the European Business Development Conference

    Read more
  • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

    Read more
  • Selvita presents at 18th Drug Discovery Summit in Berlin

    Read more
  • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

    Read more
  • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

    Read more
  • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

    Read more
  • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

    Read more
  • Selvita to present at Biotech Showcase 2017 in San Francisco

    Read more
  • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • Epidarex Capital Creates Nodthera Limite

    Read more
  • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

    Read more
  • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

    Read more
  • Selvita wins the European Rising Star Award

    Read more
  • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

    Read more
  • Merck and Selvita Announce Drug Discovery Collaboration

    Read more
  • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

    Read more
  • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

    Read more
  • Selvita receives the Economic Award of the President of Poland

    Read more
  • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

    Read more
  • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

    Read more
  • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

    Read more
  • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

    Read more
    • Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

      Read more
    • Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

      Read more
    • Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

      Read more
    • Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023

      Read more
    • Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120

      Read more
    • Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)

      Read more
    • Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

      Read more
    • Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

      Read more
    • Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

      Read more
    • Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine

      Read more
    • Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology

      Read more
    • Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy

      Read more
    • Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology

      Read more
    • Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

      Read more
    • Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

      Read more
    • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

      Read more
    • Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

      Read more
    • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics Named the Stock Exchange Company of the Year

      Read more
    • Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

      Read more
    • Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million

      Read more
    • Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics initiates public offering of shares

      Read more
    • BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates

      Read more
    • Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

      Read more
    • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

      Read more
    • Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

      Read more
    • Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission

      Read more
    • EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million

      Read more
    • Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

      Read more
    • Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

      Read more
    • Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

      Read more
    • Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

      Read more
    • Ryvu Therapeutics to Participate in Upcoming Investor Conferences

      Read more
    • Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

      Read more
    • Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      Read more
    • Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

      Read more
    • Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

      Read more
    • Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

      Read more
    • Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

      Read more
    • Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

      Read more
    • Ryvu announces option to license inflammation program exercised by Galapagos NV

      Read more
    • Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

      Read more
    • Ryvu Therapeutics Reports Q3 2021 Financial Results

      Read more
    • Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

      Read more
    • Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

      Read more
    • Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

      Read more
    • Ryvu Therapeutics Reports 2021 Half-Year Financial Results

      Read more
    • Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

      Read more
    • Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

      Read more
    • Ryvu Therapeutics to participate in upcoming global investor conferences

      Read more
    • FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Read more
    • Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

      Read more
    • Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

      Read more
    • Ryvu Therapeutics among the founding members of 30% Club Poland

      Read more
    • Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

      Read more
    • Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

      Read more
    • SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

      Read more
    • Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

      Read more
    • Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

      Read more
    • Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

      Read more
    • Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

      Read more
    • Ryvu Therapeutics Reports First Quarter 2021 Financial Results

      Read more
    • Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

      Read more
    • Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Read more
    • Ryvu Therapeutics at BIO-Europe Spring

      Read more
    • Ryvu Therapeutics reports financial results for 2020

      Read more
    • Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

      Read more
    • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

      Read more
    • Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

      Read more
    • Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

      Read more
    • Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

      Read more
    • "Dream with Ryvu" - a corporate movie by Ryvu Therapeutics

      Read more
    • Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

      Read more
    • Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

      Read more
    • Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

      Read more
    • Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

      Read more
    • Ryvu Therapeutics Reports Q3 2020 Financial Results

      Read more
    • Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

      Read more
    • Ryvu Therapeutics at BIO-Europe 2020

      Read more
    • Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

      Read more
    • First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

      Read more
    • Ryvu Therapeutics Reports 2020 Half-Year Financial Results

      Read more
    • Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

      Read more
    • Ryvu Therapeutics raised over USD 36 million from its share issue

      Read more
    • The share issue price in Ryvu Therapeutics public offering set at PLN 60

      Read more
    • Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

      Read more
    • Ryvu Therapeutics Reports First Quarter 2020 Financial Results

      Read more
    • Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

      Read more
    • NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

      Read more
    • Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

      Read more
    • Ryvu Therapeutics at BIO Digital 2020

      Read more
    • Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

      Read more
    • Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

      Read more
    • Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

      Read more
    • Galapagos and Ryvu announce research collaboration

      Read more
    • Ryvu Therapeutics Reports Annual 2019 Financial Results

      Read more
    • Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

      Read more
    • Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia

      Read more
    • Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

      Read more
    • Ryvu Therapeutics at BIO-Europe Spring 2020

      Read more
    • Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference

      Read more
    • Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept

      Read more
    • Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors

      Read more
    • Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules

      Read more
    • Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

      Read more
    • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

      Read more
    • Ryvu Therapeutics to Present at BIO-Europe 2019

      Read more
    • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

      Read more
    • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

      Read more
    • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

      Read more
    • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

      Read more
    • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

      Read more
    • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

      Read more
    • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

      Read more
    • Selvita to Present at Upcoming Conferences in September

      Read more
    • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

      Read more
    • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

      Read more
    • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

      Read more
    • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

      Read more
    • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

      Read more
    • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

      Read more
    • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

      Read more
    • Selvita to Present at Biotech Showcase 2019 in San Francisco

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more
    • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

      Read more
    • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

      Read more
    • Selvita to present new data from its oncology programs at the upcoming SITC 2018

      Read more
    • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

      Read more
    • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

      Read more
    • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

      Read more
    • Selvita publishes research results on SEL24 in Oncotarget

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

      Read more
    • Selvita Announces Successful Completion of $41 M Book Building

      Read more
    • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

      Read more
    • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

      Read more
    • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita and Menarini present together at the European Business Development Conference

      Read more
    • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

      Read more
    • Selvita presents at 18th Drug Discovery Summit in Berlin

      Read more
    • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

      Read more
    • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

      Read more
    • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

      Read more
    • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

      Read more
    • Selvita to present at Biotech Showcase 2017 in San Francisco

      Read more
    • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • Epidarex Capital Creates Nodthera Limite

      Read more
    • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

      Read more
    • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

      Read more
    • Selvita wins the European Rising Star Award

      Read more
    • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

      Read more
    • Merck and Selvita Announce Drug Discovery Collaboration

      Read more
    • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

      Read more
    • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

      Read more
    • Selvita receives the Economic Award of the President of Poland

      Read more
    • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

      Read more
    • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

      Read more
    • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more